NORDSIEK MICHAEL T,LEE JAMES H,BALAJI KODUMUDI S,WU JASON J,BABILON ROBERT,LEVY SHARON F,KULP JAMES H,MENG TZE-CHIANG,BAHM VALYN S
申请号：
ZA201301397
公开号：
ZA201301397B
申请日:
2013.02.22
申请国别(地区):
ZA
年份:
2014
代理人:
摘要：
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (&ldquo；FDA&rdquo；), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (&ldquo；FDA&rdquo；) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
